TNF Inhibitor denied for missing prior authorization by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Requires Prior Authorization for TNF Inhibitors

Anthem Blue Cross requires prior authorization (PA) for all TNF inhibitors as a standard utilization-management step — not a denial that the drug is inappropriate, but a gate requiring documented clinical justification before dispensing. A PA-required denial or lapse typically means the authorization was never submitted, was submitted with missing information, expired, or was initially denied and not appealed.

This is one of the most recoverable denial types. The path forward is either completing the PA submission correctly with full documentation, or — if the PA was denied — filing a formal appeal. Many PA denials are overturned at the internal-appeal stage when the prescriber's documentation directly addresses each Anthem criterion.

## Federal Appeal Framework

• Resubmit the PA: If the PA was never submitted or was incomplete, the fastest resolution is often a corrected PA submission by the prescribing office with complete documentation.
• Internal appeal (ERISA §503 / ACA §2719): If the PA was denied, file a formal internal appeal within the timeframe on your denial letter. You are entitled to the specific criteria used and the reviewer's qualifications.
• External independent review: Available after internal exhaustion on ACA-compliant plans. The window is generally up to approximately four months from final internal denial.
• Expedited review: If standard timelines create a serious health risk, request expedited PA and expedited appeal simultaneously in writing.

## Documentation to Gather

1. Diagnosis confirmation — specialist evaluation, objective disease findings, and ICD codes matching the TNF inhibitor's FDA-approved indication and Anthem's PA criteria. 2. Step-therapy completion — for each conventional or preferred agent Anthem requires before a biologic, document drug name, start/end dates, dosing adjustments per chart, and reason for failure (inadequate response, intolerance, or prescriber-documented contraindication). 3. Disease severity — recent office notes and objective clinical findings demonstrating the level of disease activity Anthem's PA criteria require for biologic initiation. 4. Specialist involvement — confirm the prescriber specialty matches what Anthem requires (e.g., board-certified rheumatologist, gastroenterologist, dermatologist). 5. Prescriber PA justification letter — a letter from the clinician that maps to each Anthem PA criterion by name, cites the FDA-approved indication, and references the applicable guideline organization's recommendation.

## Criteria-Mapping Structure

| Anthem PA Criterion | Chart-Based Answer | |---|---| | [Copy each requirement verbatim from Anthem's published PA criteria] | [Chart date, clinician name, exact finding addressing each criterion] |

Retrieve Anthem's current PA criteria from its provider portal or your member portal before submitting — criteria change periodically. Confirm all dosing, eligibility thresholds, and clinical requirements against the current FDA-approved prescribing label and Anthem's current published PA policy.